1 |
Berka, L., Reviews on Crystal Polymorphism of Substances in the European Pharmacopoeia. Pharm. Acta Helv., 66, 16-22 (1991)
PUBMED
|
2 |
Haleblian, J. and McCrone, W., Pharmaceutical Applications of polymorphism. J. Pharm. Sci., 58, 911-929 (1969)
DOI
PUBMED
|
3 |
Haleblian, J., Characterization of Habits and Crystalline Modification of Solids and their Pharmaceutical Application. J. Pharm. Sci., 64,1269-1288 (1975)
DOI
PUBMED
|
4 |
Shefter, E. and Higuchi, T., The Influence of Hydrate and Solvate Formation on Rates of Solution and Solubility of Drugs. J. Pharm. Sci., 52, 781-791 (1963)
DOI
PUBMED
|
5 |
Sohn, Y. T., The Effect of Pseudopolymorphism on the Relative Bioavailability of Amoxicillin. Yakhak Hoeji, 39, 438-443 (1995)
|
6 |
Sohn, Y. T. and Lee, E. H., Crystal Forms of Cefazolin Sodium Hydrates. Yakhak Hoeji, 40, 306-310 (1996)
|
7 |
Lachman, L. and Lieberman, H. A., Kanig, J. L. (Eds.): The Theory & Practice of Industrial Pharmacy, Lea & Febiger, Philadelphia. 171-196, 1986
|
8 |
Sohn, Y. T., Pharmaceutical Application of Polymorphism. Pharmacon., 21, 500-516 (1991)
|
9 |
Sohn, Y. T. and Kim, K. S., Study on Polymorphism of Cimetidine. J. Kor. Pharm. Sci., 23, 81-87 (1993)
|
10 |
Sohn, Y. T. and Kim, S. Y., Effect of Crystal Form on in VIvo Topical Anti-Inflammatory Activity of Corticosteroids. Arch. Pharm. Res.,25, 556-559 (2002)
DOI
ScienceOn
|
11 |
Kuhnert-Brandstaetter, M., Polymorphie von Arzneistoffen und ihre Bedeutung in der Pharmazeutiscen Technologie. Informationsdienst A.P.V., 19, 73-90 (1973)
|